RxDoctor Payments Data

Wuhua Jing, MD

Internal Medicine · New York, NYNPI 1164447629

Payments from drug & device makers

$337,607in general payments, 2019–2025

Across 2,078 payments — averaging $162.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$153K
  • Amgen$68K
  • Amarin Pharma, Inc.$34K
  • AbbVie$27K
  • Novo Nordisk$20K
  • Axsome Therapeutics, Inc.$11K
  • plus $25K from 52 others

What the payments were for

  • Consulting fees$14,5834%
  • Speaking & faculty fees$255,82876%
  • Travel & lodging$19,8106%
  • Food & beverage$47,32414%
  • Education$630%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead396$152,907
Amgen(2 entities)262$67,956
Amarin Pharma, Inc.84$33,717
AbbVie(2 entities)193$26,986
Novo Nordisk117$20,034
Axsome Therapeutics, Inc.29$11,383
Esperion Therapeutics, Inc.70$4,756
AstraZeneca166$3,730
Boehringer Ingelheim77$1,985
GSK75$1,330
Novartis18$1,208
Lilly USA, LLC61$1,141
Pfizer52$1,085
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC47$820
Sumitomo Pharma America, Inc.42$803
Merck36$780
Kowa Pharmaceuticals America, Inc.43$777
Bayer31$642
Arbor Pharmaceuticals, Inc.31$615
Astellas Pharma US Inc21$418
Ironwood Pharmaceuticals, Inc19$414
E.r. Squibb & Sons, L.L.C.24$381
Johnson & Johnson14$298
Nestle Healthcare Nutrition Inc.13$260
Ardelyx, Inc.10$250
Azurity Pharmaceuticals, Inc.8$182
Aimmune Therapeutics, Inc.7$175
Sanofi-aventis U.S. LLC10$175
Mannkind Corporation8$169
Radius Health, Inc.7$166
Vifor Pharma, Inc.12$164
Sunovion Pharmaceuticals Inc.8$162
Optinose US, Inc.8$158
Seqirus USA Inc8$141
Takeda Pharmaceuticals U.S.A., Inc.6$140
IBSA Pharma Inc.6$129
Avanir Pharmaceuticals, Inc.12$124
Teva Pharmaceuticals USA, Inc.5$113
Idorsia Pharmaceuticals US Inc5$110
Sanofi Pasteur Inc.5$105
Insmed, Inc.4$93
Exact Sciences3$78
Regeneron Healthcare Solutions, Inc.3$60
Corium, LLC3$58
Corcept Therapeutics2$54
Phathom Pharmaceuticals, Inc.2$46
Madrigal Pharmaceuticals2$45
Vivus LLC2$44
Travere Therapeutics, Inc.2$43
Dermavant Sciences, Inc.1$30
Sanofi1$25
Agios Pharmaceuticals, Inc.1$23
Shield Therapeutics Inc1$21
Redhill Biopharma Inc.1$21
Smith+Nephew1$21
Ultragenyx Pharmaceutical Inc.1$20
Aegerion Pharmaceuticals, Inc.1$19
Intercept Pharmaceuticals, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$337,607 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$55,314
Medicare patients
65
Services billed
792

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl1,690$1,070,857
FarxigaDapagliflozin Propanediol506$548,859
VemlidyTenofovir Alafenamide333$485,313
RybelsusSemaglutide250$374,996
CreonLipase/Protease/Amylase157$358,308
GemtesaVibegron321$261,606
Diclofenac Epolamine246$255,420
ProliaDenosumab142$241,548
Repatha SureclickEvolocumab233$223,534
LinzessLinaclotide259$208,933
JardianceEmpagliflozin201$199,700
MyrbetriqMirabegron232$183,286
EdarbiAzilsartan Medoxomil285$175,144
EliquisApixaban168$163,625
JanuviaSitagliptin Phosphate130$140,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Restasis, Ubrelvy$26,986$682,890518 claims
AstraZenecaFarxiga, Breztri Aerosphere$3,730$677,891631 claims
GileadVemlidy$152,907$485,313333 claims
Novo NordiskRybelsus, Ozempic$20,034$478,075316 claims
Sumitomo Pharma America, Inc.Gemtesa$803$261,606321 claims
AmgenProlia$67,956$241,548142 claims
Boehringer IngelheimJardiance, Tradjenta$1,985$237,502253 claims
Astellas Pharma US IncMyrbetriq$418$183,286232 claims
Arbor Pharmaceuticals, Inc.Edarbi$615$175,144285 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arexvy$1,330$170,251307 claims
PfizerEliquis$1,085$163,625168 claims
MerckJanuvia$780$140,116130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →